These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 26295963)
21. Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario. Flores Vega YI; Páramo González DL; Alsina Sarmiento SC; Alsina Tul LE; Inguanzo Valdés IB; Rodríguez Machado J; Elejalde Larrinaga Á; Flores Rodríguez JE; Lamadrid García J; Corrales Otero D; Ropero Toirac R; Crombet Ramos T; Gracia Medina EA J Cancer; 2023; 14(5):874-879. PubMed ID: 37056397 [No Abstract] [Full Text] [Related]
22. Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors. Santarpia M; Altavilla G; Pitini V; Rosell R Future Oncol; 2015; 11(8):1259-74. PubMed ID: 25832881 [TBL] [Abstract][Full Text] [Related]
23. Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients. Lorenzo-Luaces P; Sanchez L; Saavedra D; Crombet T; Van der Elst W; Alonso A; Molenberghs G; Lage A BMC Cancer; 2020 Aug; 20(1):772. PubMed ID: 32807114 [TBL] [Abstract][Full Text] [Related]
24. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068 [TBL] [Abstract][Full Text] [Related]
25. Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer. Di Maio M Expert Opin Biol Ther; 2011 Sep; 11(9):1131-3. PubMed ID: 21806477 [TBL] [Abstract][Full Text] [Related]
26. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. González G; Crombet T; Catalá M; Mirabal V; Hernández JC; González Y; Marinello P; Guillén G; Lage A Ann Oncol; 1998 Apr; 9(4):431-5. PubMed ID: 9636835 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic vaccination with an EGF-based vaccine in lung cancer: a step in the transition to a chronic disease. Rodriguez G; Gonzalez G; Crombet T; Lage A Expert Rev Respir Med; 2011 Jun; 5(3):337-42. PubMed ID: 21702656 [TBL] [Abstract][Full Text] [Related]
28. Is there a role for cetuximab in non small cell lung cancer? Morgensztern D; Govindan R Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149 [TBL] [Abstract][Full Text] [Related]
29. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Mellstedt H; Vansteenkiste J; Thatcher N Lung Cancer; 2011 Jul; 73(1):11-7. PubMed ID: 21474197 [TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update. Pirker R Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162 [TBL] [Abstract][Full Text] [Related]
32. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. Neal JW; Heist RS; Fidias P; Temel JS; Huberman M; Marcoux JP; Muzikansky A; Lynch TJ; Sequist LV J Thorac Oncol; 2010 Nov; 5(11):1855-8. PubMed ID: 20975380 [TBL] [Abstract][Full Text] [Related]
33. Therapeutic targeting of epidermal growth factor receptor with monoclonal antibodies. Siena S; Artale S; Vanzulli A; Marrapese G; Bevilacqua L; Secondino S; Sironi O; Schiavo R; Moroni M; Pedrazzoli P Suppl Tumori; 2002; 1(4):S46-8. PubMed ID: 12415818 [No Abstract] [Full Text] [Related]
34. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Dienstmann R; Felip E Expert Opin Biol Ther; 2011 Sep; 11(9):1223-31. PubMed ID: 21679088 [TBL] [Abstract][Full Text] [Related]
35. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials. De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114 [TBL] [Abstract][Full Text] [Related]
36. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Hall RD; Gray JE; Chiappori AA Cancer Control; 2013 Jan; 20(1):22-31. PubMed ID: 23302904 [TBL] [Abstract][Full Text] [Related]
38. Clinical relevance of monoclonal antibodies in non small cell lung cancer. Filipits M J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057 [TBL] [Abstract][Full Text] [Related]
39. Harnessing the immune system for the treatment of non-small-cell lung cancer. Brahmer JR J Clin Oncol; 2013 Mar; 31(8):1021-8. PubMed ID: 23401435 [TBL] [Abstract][Full Text] [Related]
40. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR). Zhu L; Zhao L; Wu M; Chen Z; Li H Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]